Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

James G Krueger, Leon Kircik, Firas Hougeir, Adam Friedman, Xiaojun You, Nisha Lucas, Steven J Greenberg, Marianne Sweetser, Wanda Castro-Borrero, Peter McCroskery, Jacob Elkins, James G Krueger, Leon Kircik, Firas Hougeir, Adam Friedman, Xiaojun You, Nisha Lucas, Steven J Greenberg, Marianne Sweetser, Wanda Castro-Borrero, Peter McCroskery, Jacob Elkins

Abstract

Introduction: Cutaneous adverse events (AEs) have been observed in clinical studies of daclizumab high-yield process (HYP) in relapsing-remitting multiple sclerosis (RRMS). Here, we report cutaneous AEs observed in the randomized, double-blind, active-comparator DECIDE study (ClinicalTrials.gov identifier, NCT01064401).

Methods: DECIDE was a randomized, double-blind, active-controlled phase 3 study of daclizumab HYP 150 mg subcutaneous every 4 weeks versus interferon (IFN) beta-1a 30 mcg intramuscular (IM) once weekly in RRMS. Treatment-emergent AEs were classified and recorded by investigators. Investigators also assessed the severity of each AE, and whether it met the criteria for a serious AE. Cutaneous AEs were defined as AEs coded to the Medical Dictionary for Regulatory Activities System Organ Class of skin and subcutaneous tissue disorders. The incidence, severity, onset, resolution, and management of AEs were analyzed by treatment group.

Results: Cutaneous AEs were reported in 37% of daclizumab HYP-treated patients and 19% of IFN beta-1a-treated patients. The most common investigator-reported cutaneous AEs with daclizumab HYP were rash (7%) and eczema (4%). Most patients with cutaneous AEs remained on treatment (daclizumab HYP, 81%; IM IFN beta-1a, 90%) and had events that were mild or moderate (94% and 98%) and subsequently resolved (78% and 82%). Most patients with cutaneous AEs did not require treatment with corticosteroids or were treated with topical corticosteroids (daclizumab HYP, 73%; IM IFN beta-1a, 81%). Serious cutaneous AEs were reported in 14 (2%) daclizumab HYP patients and one (<1%) IM IFN beta-1a patient.

Conclusion: There was an increased risk of cutaneous AEs with daclizumab HYP. While physicians should be aware of the potential for serious cutaneous AEs, the typical cutaneous AEs were mild-to-moderate in severity, manageable, and resolved over time.

Funding: Biogen and AbbVie Biotherapeutics Inc.

Trial registration: ClinicalTrials.gov identifier, NCT01064401.

Keywords: Cutaneous events; Daclizumab high-yield process; Dermatology; Interferon beta; Neurology; Relapsing-remitting multiple sclerosis; Safety.

Figures

Fig. 1
Fig. 1
Incidence of all cutaneous AEs (a) and moderate or severe cutaneous AEs (b) by 12-week intervals during the treatment period. The numbers of patients represents the safety population evaluated during those intervals. AE adverse event, HYP high-yield process, IFN interferon, IM intramuscular
Fig. 2
Fig. 2
Corticosteroid treatment in patients with cutaneous AEs by AE severity and for serious cutaneous AEs. AE adverse event, HYP high-yield process, IFN interferon, IM intramuscular

References

    1. Wiendl H, Gross CC. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol. 2013;9:394–404. doi: 10.1038/nrneurol.2013.95.
    1. Waldmann TA. The IL-2/IL-15 receptor systems: targets for immunotherapy. J Clin Immunol. 2002;22:51–56. doi: 10.1023/A:1014416616687.
    1. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci USA. 1999;96:7462–7466. doi: 10.1073/pnas.96.13.7462.
    1. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon ß. Proc Natl Acad Sci USA. 2004;101:8705–8708. doi: 10.1073/pnas.0402653101.
    1. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol. 2004;56:864–867. doi: 10.1002/ana.20287.
    1. Gold R, Giovannoni G, Selmaj K, SELECT study investigators et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167–2175. doi: 10.1016/S0140-6736(12)62190-4.
    1. Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418–1428. doi: 10.1056/NEJMoa1501481.
    1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice. . Accessed 1 Nov 2014.
    1. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–846. doi: 10.1002/ana.20703.
    1. Kardaun SH, Sekula P, Valeyrie-Allanore L, RegiSCAR study group et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071–1080. doi: 10.1111/bjd.12501.
    1. McEwan L, Brown J, Poirier J, et al. Best practices in skin care for the multiple sclerosis patient receiving injectable therapies. Int J MS Care. 2010;12:177–189. doi: 10.7224/1537-2073-12.4.177.
    1. Cortese I, Ohayon J, Fenton K, et al. Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology. 2016;86:847–855. doi: 10.1212/WNL.0000000000002417.
    1. Oh J, Saidha S, Cortese I, et al. Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis. Neurology. 2014;82:984–988. doi: 10.1212/WNL.0000000000000222.
    1. Edwards LJ, Constantinescu CS. A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. Mult Scler. 2004;10:575–581. doi: 10.1191/1352458504ms1087oa.
    1. Ramagopalan SV, Dyment DA, Valdar W, Canadian Collaborative Study Group et al. Autoimmune disease in families with multiple sclerosis: a population-based study. Lancet Neurol. 2007;6:604–610. doi: 10.1016/S1474-4422(07)70132-1.
    1. Clark RA. Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol. 2010;130:362–370. doi: 10.1038/jid.2009.247.
    1. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA. 2006;103:5941–5946. doi: 10.1073/pnas.0601335103.
    1. Elkins J, Sheridan J, Amaravadi L, et al. CD56bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2015;2:e65. doi: 10.1212/NXI.0000000000000065.
    1. Huss DJ, Mehta DS, Sharma A, et al. In vivo maintenance of human regulatory T cells during CD25 blockade. J Immunol. 2015;194:84–92. doi: 10.4049/jimmunol.1402140.
    1. Oh U, Blevins G, Griffith C, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol. 2009;66:471–479. doi: 10.1001/archneurol.2009.16.
    1. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–1494. doi: 10.1056/NEJMra074081.
    1. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134:769–779. doi: 10.1016/j.jaci.2014.08.008.
    1. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116–132. doi: 10.1016/j.jaad.2014.03.023.
    1. Menter A, Korman NJ, Elmets CA, American Academy of Dermatology et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–659. doi: 10.1016/j.jaad.2008.12.032.
    1. Sidbury R, Davis DM, Cohen DE, American Academy of Dermatology et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71:327–349. doi: 10.1016/j.jaad.2014.03.030.
    1. Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol. 2005;53(suppl 1):S3–S16. doi: 10.1016/j.jaad.2005.04.026.
    1. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134:1527–1534. doi: 10.1038/jid.2013.446.
    1. Margolis JS, Abuabara K, Bilker W, Hoffstad O, Margolis DJ. Persistence of mild to moderate atopic dermatitis. JAMA Dermatol. 2014;150:593–600. doi: 10.1001/jamadermatol.2013.10271.
    1. Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18:82–91. doi: 10.2310/6620.2007.06034.
    1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866–873. doi: 10.1038/nature05663.
    1. Girardi M. Cutaneous perspectives on adaptive immunity. Clin Rev Allergy Immunol. 2007;33:4–14. doi: 10.1007/s12016-007-0040-9.
    1. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis—part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011;127:1420–1432. doi: 10.1016/j.jaci.2011.01.054.
    1. Freyschmidt EJ, Mathias CB, Diaz N, et al. Skin inflammation arising from cutaneous regulatory T cell deficiency leads to impaired viral immune responses. J Immunol. 2010;185:1295–1302. doi: 10.4049/jimmunol.0903144.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다